drugset / Trial / NCT05393635
ITIL-168 in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).
Timeline
- Start
- 2022-08
- Primary completion
- 2022-12-08
- Completion
- 2022-12-08
Outcome
Outcome not reported
Stopped (Business): “business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ITIL-168 | Cell therapy | — | — |